Edaravone-Sodium Ozagrel Comparative Post-Marketing Study on Acute Ischemic Stroke
Status:
Completed
Trial end date:
2006-10-01
Target enrollment:
Participant gender:
Summary
This study is randomized, Sodium Ozagrel (Thromboxane A2 Synthase Inhibitor) controlled study
on acute ischemic stroke. The primary endpoints were the rate of patients with modified
Rankin Scale score of 0-1 at 3 months.